Soligenix (SNGX) investor relations material

Executive summary

• Net loss for Q1 2026 was $2.8 million, a decrease year-over-year, mainly due to lower operating expenses.

• Interim analysis of the Phase 3 FLASH2 trial for HyBryte in CTCL led to a recommendation to halt the study for futility, with further data analysis ongoing.

• SGX945 (dusquetide) for Behçet's Disease received orphan drug and PIM designations, with promising Phase 2 results.

• SGX302 (synthetic hypericin) for psoriasis showed good tolerability in a Phase 2a trial, supporting further evaluation.

• Cash and cash equivalents were $6.0 million as of March 31, 2026, with runway projected into Q2 2027.

Financial highlights

• No revenue reported for Q1 2026 or Q1 2025.

• Research and development expenses decreased to $1.78 million from $1.94 million year-over-year, mainly due to lower third-party manufacturing and completed studies.

• General and administrative expenses were flat at $1.1 million.

• Net loss per share improved to $(0.28) from $(0.97) year-over-year, reflecting a higher share count.

• Cash used in operating activities was $2.36 million for Q1 2026.

Outlook and guidance

• Management expects continued losses and negative cash flow, with liquidity dependent on new capital, grants, or strategic transactions.

• Strategic options under evaluation include mergers, acquisitions, and advancing pipeline assets.

• Research and development expenditures for the next 12 months are projected at $2.0 million, focused on Specialized BioTherapeutics.

• Continued focus on advancing SGX945 and SGX302 in rare and underserved disease markets.

• Further analysis of FLASH2 data may inform next steps for HyBryte and regulatory discussions.